Tohma, Yusuf Aytaç

Profile Picture
Profile URL
https://hdl.handle.net/20.500.14411/7261
Name Variants
Y., Tohma
T.,Yusuf Aytaç
Y.A.Tohma
Aytac Tohma Y.
Tohma Y.
Yusuf Aytaç, Tohma
Y. A. Tohma
T., Yusuf Aytaç
Tohma, Y. Aytaç
Aytac Tohma, Yusuf
Tohma, Yusuf A.
Tohma, Yusuf Aytac
Tohma, Yusuf Aytaç
Y.,Tohma
Yusuf Aytac, Tohma
T.,Yusuf Aytac
Tohma, Y. A.
T., Yusuf Aytac
Tohma,Y.A.
Job Title
Doçent Doktor
Email Address
aytac.tohma@atilim.edu.tr
Main Affiliation
Department of Medical Services and Techniques
Status
Website
ORCID ID
Scopus Author ID
55834891800
Turkish CoHE Profile ID
Google Scholar ID
WoS Researcher ID

Sustainable Development Goals

NO POVERTY1
NO POVERTY
0
Research Products
ZERO HUNGER2
ZERO HUNGER
0
Research Products
GOOD HEALTH AND WELL-BEING3
GOOD HEALTH AND WELL-BEING
2
Research Products
QUALITY EDUCATION4
QUALITY EDUCATION
0
Research Products
GENDER EQUALITY5
GENDER EQUALITY
0
Research Products
CLEAN WATER AND SANITATION6
CLEAN WATER AND SANITATION
0
Research Products
AFFORDABLE AND CLEAN ENERGY7
AFFORDABLE AND CLEAN ENERGY
0
Research Products
DECENT WORK AND ECONOMIC GROWTH8
DECENT WORK AND ECONOMIC GROWTH
0
Research Products
INDUSTRY, INNOVATION AND INFRASTRUCTURE9
INDUSTRY, INNOVATION AND INFRASTRUCTURE
0
Research Products
REDUCED INEQUALITIES10
REDUCED INEQUALITIES
0
Research Products
SUSTAINABLE CITIES AND COMMUNITIES11
SUSTAINABLE CITIES AND COMMUNITIES
0
Research Products
RESPONSIBLE CONSUMPTION AND PRODUCTION12
RESPONSIBLE CONSUMPTION AND PRODUCTION
0
Research Products
CLIMATE ACTION13
CLIMATE ACTION
0
Research Products
LIFE BELOW WATER14
LIFE BELOW WATER
0
Research Products
LIFE ON LAND15
LIFE ON LAND
0
Research Products
PEACE, JUSTICE AND STRONG INSTITUTIONS16
PEACE, JUSTICE AND STRONG INSTITUTIONS
0
Research Products
PARTNERSHIPS FOR THE GOALS17
PARTNERSHIPS FOR THE GOALS
0
Research Products
Documents

51

Citations

391

h-index

11

Go to Scopus profile
This researcher does not have a WoS ID.
Scholarly Output

5

Articles

5

Views / Downloads

12/0

Supervised MSc Theses

0

Supervised PhD Theses

0

WoS Citation Count

11

Scopus Citation Count

15

Patents

0

Projects

0

WoS Citations per Publication

2.20

Scopus Citations per Publication

3.00

Open Access Source

3

Supervised Theses

0

JournalCount
Frontiers in Endocrinology2
BMC Pregnancy and Childbirth1
Journal of Assisted Reproduction and Genetics1
Turkish Journal of Obstetrics and Gynecology1
Current Page: 1 / 1

Scopus Quartile Distribution

Competency Cloud

GCRIS Competency Cloud

Filters

2024 - 20255
Reset filters

Settings

COAR Resource Type: text::journal::journal article

Scholarly Output Search Results

Now showing 1 - 5 of 5
  • Thumbnail Image
    Article
    Citation - WoS: 4
    Citation - Scopus: 5
    Individualized Luteal Phase Support in Frozen-Thawed Embryo Transfer After Intramuscular Progesterone Administration Might Rectify Live Birth Rate
    (Frontiers Media Sa, 2024) Boynukalin, Fazilet Kubra; Tohma, Yusuf Aytac; Yarkiner, Zalihe; Gultomruk, Meral; Bozdag, Gurkan; Ozkavukcu, Sinan; Demir, Berfu
    Background: The serum P concentrations are suggested to have an impact on pregnancy outcome. However there is no consensus about the optimal progesterone cut-off during the luteal phase. Few studies evaluated the effectiveness of a "rescue protocol" for low serum P concentrations and most of these studies used vaginal progesterone administration. There is paucity of data on the effectiveness of rescue protocol using intramuscular progesterone (IM-P) in frozen-thawed embryo transfer (FET). Methods: This study is a retrospective cohort study included 637 single or double blastocyst FETs with artificially prepared endometrium receiving 100 mg IM progesterone (P) after incremental estrogen treatment. Serum P concentrations were evaluated using blood samples obtained 117-119 hours after the first IM-P administration and 21 +/- 2 hours after the last IM-P administration. Patients with serum P concentrations <20.6 ng/ml on the ET day were administrated 400 mg vaginal progesterone for rescue. Results: Demographic and cycle characteristics were similar between patients receiving rescue vaginal P (embryo transfer (ET)-day P concentration < 20.6 ng/ml) and patients who did not need rescue vaginal P (ET-day P concentration >= 20.6 ng/ml). Clinical pregnancy, miscarriage, and live birth rates were similar between two groups: 52.9%(45/85) vs 59.6%(326/552), p=0.287; 11.1%(5/45) vs 14.1%(46/326), p=0.583; and 47.1%(40/85) vs 50.7%(280/552), p=0.526, respectively. Logistic regression analysis revealed that the female age (p = 0.008, OR=0.942, 95% CI = 0.902-0.984) and embryo quality (ref: good quality for moderate: p=0.02, OR=0.469, 95% CI =0.269-0.760; for poor: p=0.013, OR= 0.269, 95% CI = 0.092-0.757) were independent variables for live birth. Following rescue protocol implementation, ET-day P concentration was not a significant predictor of live birth. Conclusions: Rescue vaginal P administration for low ET day serum P concentrations following IM-P yields comparable live birth rates.
  • Thumbnail Image
    Article
    Citation - WoS: 6
    Citation - Scopus: 7
    A Novel Technique- Subendometrial Autologous Platelet Rich Plasma Injection in Patients With Unresponsive Thin Endometrium Undergoing Frozen-Thawed Embryo Transfer: a Prospective Cohort Study
    (BMC, 2025) Cakiroglu, Yigit; Tohma, Yusuf Aytac; Yuceturk, Aysen; Karaosmanoglu, Ozge; Aslan, Ilke Ozer; Kopuk, Sule Yildirim; Tiras, Bulent
    Background The purpose of this study was to investigate the effects of subendometrial PRP injection on endometrial thickness and pregnancy outcomes in patients with a history of unresponsive thin endometrium undergoing frozen-thawed embryo transfer (FET). Methods This prospective cohort study was conducted at Acibadem Mehmet Ali Aydinlar University-Istanbul, Turkey. Women with a history of suboptimal endometrial proliferation (< 7 mm) were offered to participate in the study. Group 1 consisted of 100 individuals who consented to subendometrial PRP injection, while Group 2 consisted of 100 individuals who did not accept PRP injection. Within ten days of the menstrual cycle ending, autologous PRP was produced by centrifuging peripheral blood and administered transvaginally into the subendometrial region under ultrasound monitoring. After the PRP procedure, 14 days of oral estradiol supplementation were started as part of the hormonal treatment on the 2-4th day of the second menstrual cycle. Women determined to have adequate endometrial thickness following the initiation were scheduled for embryo transfers. Embryo transfer was scheduled for women who were found to have adequate endometrial thickness after the initiation of progesterone. Pregnancy (positive serum hCG) and livebirth rates were followed. Results A total of 200 women (age 36.4 +/- 5.8) were included in the study. Endometrial thickness increased after PRP therapy as compared to the control group (7.7 +/- 1.9 mm vs. 6.1 +/- 1.2 mm; p < 0.01). Three women (3.0%) in the PRP group conceived spontaneously, whereas 97 women (97.0%) attempted FET; no spontaneous pregnancies occurred in the control group. Compared to 75/100 (75% of the total) in the control group, 33/97 women (34.0%) in the PRP group were unable to undertake ET because of persistently unresponsive thin endometrium or fluid in the endometrial cavity (p < 0.001). The PRP group had a considerably higher percentage of positive serum hCG tests than the control group (25.8% vs. 9.0%; p = 0.002). Additionally, the PRP group had a higher clinical pregnancy rate (22.7% vs. 7.0%; p = 0.002). The live birth rate was significantly higher in the PRP group than the controls (17.5% vs. 2.0%; p < 0.001). Conclusions In women with a history of suboptimal endometrial development, subendometrial PRP injection was associated with improved endometrial thickness and livebirth rate.
  • Thumbnail Image
    Article
    Citation - WoS: 1
    Citation - Scopus: 1
    A Comparative Analysis of Progestin-Primed Ovarian Stimulation Versus GnRH Antagonists Protocols Pertaining To Stimulation Parameters and Embryological Outcomes in Patients With Endometrioma
    (Frontiers Media SA, 2025) Boynukalin, Fazilet Kübra; Tohma, Yusuf Aytaç; Gültomruk, Meral; Yarkiner, Zalihe; Akkaya, Ceren Melisa; Özkavukçu, Sinan; Bozdaǧ, Gürkan
    Research question: Do embryo parameters and live birth rates differ between patients with endometrioma undergoing a freeze-all strategy using either GnRH antagonists or progestin-primed ovarian stimulation (PPOS)? Design: This retrospective cohort study was conducted at Bahceci Health Group from January 2021 to January 2023. Inclusion criteria were females aged 20–40 with confirmed endometriosis, using either GnRH antagonists or PPOS ovarian stimulation, and opting for freezing all embryos without fresh embryo transfer (ET). A total of 543 patients were analyzed, with the primary outcome being usable embryos at cleavage stage and secondary outcomes including distribution of embryo quality, clinical pregnancy, and live birth rate. Results: For the GnRH antagonist arm, the median (25th-75th percentiles) total gonadotropin dose required during stimulation was significantly higher (2725 [2100–3587.5] vs. 2400 [2050–3075] IU, p = 0.001) and duration was longer (11 [10–12] vs. 10 [9–11] days, p = 0.01), although number of mature oocytes and maturation and fertilization rates were similar in both arms. However, the linear regression analysis revealed that the number of usable day-three embryos was higher with the PPOS protocol than with the GnRH antagonist protocol (OR: 0.890, CI 95%: 0.226 – 1.554, p= 0.009). Particularly in patients that had undergone FET, the respective live birth rates were 50.0% and 54.6% in GnRH antagonist and PPOS arms, respectively, without any statistical significance (p= 0.365). Conclusion: In patients with endometrioma, the PPOS protocol over GnRH antagonists might potentially enhance the quantity of usable cleavage-stage embryos while showing no significant impact on the number of collected oocytes. © 2025 Elsevier B.V., All rights reserved.
  • Thumbnail Image
    Article
    Citation - Scopus: 2
    Yapay Dondurulmuş-Çözdürülmüş Blastokist Transferi Yapılan Hastalarda Embriyo Transferi Günündeki Yüksek Serum Progesteron Düzeyleri: Tavan Etkisi Var Mı
    (Turkish Society of Obstetrics and Gynecology, 2024) Findikli, Necati; Demir, Berfu; Tohma, Yusuf Aytaç; Bozdag, Gurkan; Bahcecı, Mustafa; Dündar, Betül; Boynukalin, Fazilet Kubra
    Amaç: Yapay dondurulmuş-çözünmüş blastosist transferi (FET) siklusu uygulanan hastalarda embriyo transfer gününde yüksek serum progesteron düzeylerinin gebelik sonuçları üzerindeki tavan etkisi olup olmadığını değerlendirmeyi amaçladık. Gereç ve Yöntemler: Bu çalışma yapay FET döngüsü uygulanan 595 hastayı içeren retrospektif bir kohort çalışmasıydı. Progesteron düzeylerine göre yüzdelik dilimleri değerlendirdiğimizde 40,6 ng/mL 90. yüzdeliğe, 23,9 ng/mL ise 50. yüzdeliğe karşılık geliyordu. Bu bulguya dayanarak progesteron düzeyi kesme noktasını <20 ng/mL, n=220 (%37,0); 20-40 ng/mL, n=312 (%52,4) ve ≥40 ng/mL, n=63 (%10,6) olarak belirledik. Birincil sonuç ölçüsü, klinik gebelik (CPR) ve canlı doğum oranı (LBR) olarak belirlendi. Bulgular: Blastokist morfolojisi olarak genişleme derecesi, trofoektoderm ve iç hücre kitle derecesi klinik gebelik ile istatistiksel olarak anlamlı düzeyde ilişkili olduğunu bulduk (hepsi için p<0,001) ve 20-40 ng/mL arasındaki progesteron düzeyinin ise daha yüksek CPR ile ilişkili olduğunu bulduk (p=0,043). Çok değişkenli analizde; CPR ile ilişkili faktörler yalnızca blastosist genişlemesi ve iç hücre kütle derecesi bağımsız ve anlamlı faktörlerdi [p=0,011, (odds oranı) OO=1,6, güven aralığı (GA) 95%=1,13-2,39 ve p=0,007, OO=1,65, GA 95%=1,14-2,39, sırasıyla]. Progesteron düzeyi ve trofoektoderm derecesi istatistiksel olarak anlamlı bulunmadı. Faktörler ile LBR arasındaki ilişkinin değerlendirilmesinde sadece blastokist genişleme derecesi 4’e eşit veya üzerinde ve trofektoderm derecesi A veya B istatistiksel olarak anlamlı LBR ile ilişkiliydi. Sonuç: Bu verilere göre yapay FET siklusu yapılan hastalarda embriyo transferi gününde serum P4 düzeyi 40 ng/mL’nin üzerinde ise kullanılan progesteron dozunun azaltılmasına gerek olmadığını düşündük.
  • Thumbnail Image
    Article
    Serum Progesterone Variability on Embryo Transfer Day in Hormone Replacement Therapy Cycles Using Intramuscular Injections During Frozen Embryo Transfers
    (Springer/plenum Publishers, 2025) Boynukalin, Fazilet Kubra; Tohma, Yusuf Aytac; Demir, Berfu; Gultomruk, Meral; Polyzos, Nikolaos P.; Bahceci, Mustafa; Bozda, Gurkan; Bozdağ, Gürkan
    Purpose To assess the intra-individual variability of serum progesterone (P) levels on embryo transfer (ET) day, when the same dose of intramuscular progesterone (IM-P) was used in two consecutive hormone replacement therapy (HRT) frozen embryo transfer (FET) cycles. Methods A total of 75 patients undergoing two consecutive HRT-FET cycles in one year performed at Bahceci Ankara IVF Center between November 2019 and February 2022 were retrospectively analyzed. Serum P levels were measured at the 117th-119th hours of support by a single laboratory. The two measurements of P levels performed on the day of the first and the second FET were compared to evaluate the intra-individual variability of serum P levels. Results Comparisons between the 1st and 2nd FET cycles revealed statistically significant intra-individual variation, with an average difference of -2.47 ng/mL (95% CI: -4.65 to -0.29, p = 0.027) between the two consecutive measurements. To assess their consistency, the limit of agreement was also tested with the Bland-Altman method, in which the mean difference (+ 1.96 x SD and -1.96 x SD) was -2.47 (16.1 and -21.1). Based on a previous study, the frequency of low P levels, as expressed by being > 20.6 ng/mL on ET day, was similar between the 1st and 2nd FET cycles (14.7% vs. 9.3%, p = 0.31). Notably, most patients had improved P levels in the second cycle if initially low, while decreases were rare among those with initially higher levels. Conclusion Serum P levels may vary within the same individual across FET cycles despite the use of the same dosage of IM-P. Increasing maternal age, high body mass index, and fluctuating estradiol levels on the day of ET were identified as risk factors contributing to this variability.